Potential use of serum insulin-like growth factor 1 and E-cadherin as biomarkers of colorectal cancer.
Colorectal cancer
E-cadherin
IGF-1
diagnostic accuracy
prediction
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
08
03
2020
accepted:
26
05
2020
pubmed:
16
9
2020
medline:
19
8
2021
entrez:
15
9
2020
Statut:
ppublish
Résumé
Despite many efforts, reliable biomarkers for the prediction and diagnosis of colorectal cancer (CRC) are still missing. Insulin-like growth factor 1 (IGF-1) and E-cadherin are recognized as potential biomarkers, but their diagnostic capacity is largely unexplored in CRC. The aim of this work is to investigate IGF-1 and E-cadherin levels with respect to various characteristics of CRC and to estimate their diagnostic potential. Seventy CRC patients and 75 healthy individuals were enrolled. IGF-1 and E-cadherin were determined using enzyme-linked immunosorbent assay. The predictive and diagnostic capacities of IGF-1 and E-cadherin were estimated by logistic regression analysis and by determination of the area under the receiver operating characteristic (ROC) curve (AUC). Concentrations of IGF-1 were lower (P = 0.019) while levels of E-cadherin were higher (P < 0.001) in CRC patients than in controls. IGF-1 concentration decreased in parallel with age and progression of CRC (P = 0.023). Also, IGF-1 was higher in men with CRC than in women (P = 0.003). E-cadherin levels were unaffected by variations in either anthropometric characteristics of CRC patients, or localization, grade and stage of the tumour. Both IGF-1 and E-cadherin were independently associated with CRC (P = 0.040; P < 0.001, respectively). The diagnostic accuracy of IGF-1 was estimated as acceptable (AUC = 0.757; P < 0.001), while the diagnostic accuracy of E-cadherin was outstanding (AUC = 0.954; P < 0.001). Decreased IGF-1 and increased E-cadherin levels were found in CRC patients. IGF-1, but not E-cadherin, concentrations differed according to age, gender and stage of CRC. Both markers were independently associated with the presence of the disease, while E-cadherin demonstrated high diagnostic accuracy.
Substances chimiques
Biomarkers, Tumor
0
Cadherins
0
IGF1 protein, human
0
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2078-2086Informations de copyright
© 2020 The Association of Coloproctology of Great Britain and Ireland.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother 2017; 87: 8-19.
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383: 1490-1502.
Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011; 7: 11-24.
Chaves J, Saif MW. IGF system in cancer: from bench to clinic. Anticancer Drugs 2011; 22: 206-12.
Jochem C, Leitzmann M. Obesity and colorectal cancer. Recent Results Cancer Res 2016; 208: 17-41.
Viesti A. Collares R, Salgado W, Pretti da Cunha Tirapelli D, dos Santos JS. The Expression of LEP, LEPR, IGF1 and IL10 in Obesity and the Relationship with microRNAs. PLoS One 2014; 9: e93512.
Tarasiuk A, Mosińska P, Fichna J. The mechanisms linking obesity to colon cancer: An overview. Obes Res Clin Pract 2018; 12: 251-9.
Hu J, Liu X, Chi J et al. Expressions of IGF-1, ERK, GLUT4, IRS-1 in metabolic syndrome complicated with colorectal cancer and their associations with the clinical characteristics of CRC. Cancer Biomark 2018; 21: 883-91.
Li ZJ, Ying XJ, Chen HL et al. Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer. World J Gastroenterol 2013; 19: 7788-94.
Rinaldi S, Cleveland R, Norat T et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010; 126: 1702-15.
Yosry A, Omran D, Yousef M et al. SNPs in the insulin-like growth factor gene and obesity impact on colorectal cancer in Egyptians. Asian Pac J Cancer Prev 2017; 18: 2959-64.
Pankaj J, Kumari JR, Kim W, Lee SA. Insulin-like Growth Factor-1, IGF-binding Protein-3, C-peptide and colorectal cancer: a case-control study. Asian Pac J Cancer Prev 2015; 16: 3735-40.
Nagle AM, Levine KM, Tasdemir N et al. Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R/InsR inhibitors. Clin Cancer Res 2018; 24: 5165-77.
Le Coz V, Zhu C, Devocelle A et al. IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process. Oncotarget 2016; 7: 82511-27.
Nurwidya F, Takahashi F, Kobayashi I et al. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer. Biochem Biophys Res Commun 2014; 455: 332-8.
Yu W, Yang L, Li T, Zhang Y. Cadherin signaling in cancer: its functions and role as a therapeutic target. Front Oncol 2019; 9: 989.
Daulagala AC, Bridges MC, Kourtidis A. E-cadherin beyond structure: a signaling hub in colon homeostasis and disease. Int J Mol Sci 2019; 20: 2756.
Kwak JM, Min BW, Lee JH et al. The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum 2007; 50: 1873-80.
Repetto O, De Paoli P, De Re V, Canzonieri V, Cannizzaro R. Levels of soluble E-cadherin in breast, gastric, and colorectal cancers. BioMed Res Int 2014; 2014: 1-7.
Stevanovic M, Vekic J, Bogavac-Stanojevic N et al. Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development. Biochemia Medica 2018; 28: 30703.
Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 2010; 5: 1315-6.
Pankaj J, Kumari JR, Kim W, Lee SA. Insulin-like Growth Factor-1, IGF-binding Protein-3, C-peptide and colorectal cancer: a case-control study. Asian Pac J Cancer Prev 2015; 16: 3735-40.
Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014; 14: 754-62.
Schwarz S, Prokopchuk O, Esefeld K et al. The clinical picture of cachexia: a mosaic of different parameters (experience of 503 patients). BMC Cancer 2017; 17: 130.
Bidlingmaier M, Friedrich N, Emeny RT et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 2014; 99): 1712-21.
Zhu H, Xu Y, Gong F, et al. Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults. PLOS One 2017; 12: e0185561.
Elzagheid A, Buhmeida A, Laato M et al. Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma. APMIS 2012; 120: 539-48.
Yun JA, Kim SH, Hong HK et al. Loss of E-cadherin expression is associated with a poor prognosis in stage III colorectal cancer. Oncology 2014; 86: 318-28.
Okugawa Y, Toiyama Y, Inoue Y et al. Clinical significance of serum soluble E-cadherin in colorectal carcinoma. J Surg Res 2012; 175: e67-e73.
Weiss JV, Klein-Scory S, Kübler S et al. Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer 2011; 128: 1384-92.
Cepowicz D, Zaręba K, Pryczynicz A et al. Blood serum levels of E-cadherin in patients with colorectal cancer. Prz Gastroenterol 2017; 12: 186-91.